DPP-4 inhibitors have also been examined in placebo-controlled studies in subjects with type 2 diabetes and chronic renal insufficiency, including patients with end-stage renal disease on dialysis (118–121). This evidence concerns the gene DPP4 and type 2 diabetes mellitus.